Corbus Q3 net loss $13.8M; CRB-701 dose escalation complete; cash $159.4M

Corbus Pharmaceuticals Holdings, Inc.

2024-Q3 EPS reported -$2.92

Net loss of $13.8M ($1.15/diluted share) vs $10.1M ($2.27) in Q3 2023; operating expenses up $6.0M to $15.5M.
Cash, cash equivalents and investments $159.4M; expects to fund operations through Q3 2027.
Raised $35.6M net proceeds via ATM program in Q3 by issuing 663,730 shares.
Completed enrollment in CRB-701 dose escalation part of Phase 1; first data expected in Q1 2025.
Final $11.8M loan payment made; loan fully paid off.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.